This trial is active, not recruiting.

Conditions human papillomavirus, hiv-1 infection
Treatment gardasil vaccine
Phase phase 4
Sponsor Kenyatta National Hospital
Collaborator University of Washington
Start date December 2014
End date November 2018
Trial size 179 participants
Trial identifier NCT01446718, (MISP)IISP 51802, NCT01998178


The purpose of this study is to determine sustained immunogenicity of the quadrivalent vaccine 'Gardasil', 48 months after initial vaccination, among HIV-1 infected boys and girls age 9-14 years. This age range is within the World Health Organization (WHO) stipulated guidelines for national programs for the vaccine.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
This is an extension of follow up for participants who received 3 doses of Gardasil vaccine in the "Immunogenicity and Safety of Quadrivalent Human Papillomavirus Vaccine in HIV-Infected Pre-Adolescent Girls and Boys in Kenya" study.
gardasil vaccine Gardasil
0.5ml of intramuscular vaccine in three doses

Primary Outcomes

immune response to vaccine specific HPV types
time frame: 48 months

Secondary Outcomes

immune response to vaccine specific HPV types
time frame: 48 months

Eligibility Criteria

Male or female participants from 9 years up to 14 years old.

Inclusion Criteria: - HIV-infected - age 9-14 years - guardian/parental consent Exclusion Criteria: Participants will be excluded if they - are severely ill as defined by Karnofsky <70 - have a diagnosis of malignancy - on-going febrile illness (temperature ≥37.8°C), including active treatment for an opportunistic infection - have received systemic corticosteroids within prior one year - have received inactivated vaccine within prior 2 weeks, or live attenuated vaccine within prior 6 weeks - have history of allergy to any products included in the HPV vaccine - have received any of blood derivatives within prior 6 months - are pregnant - lack parental consent and/or parent declines to provide assent

Additional Information

Official title A Longitudinal Observational Cohort Study to Assess Sustained Immunogenicity up to 48 Months to Quadrivalent Human Papillomavirus Vaccine Among HIV-infected Girls and Boys Age 9-14 Years in Kenya
Principal investigator Nelly R Mugo, MMed, MPH
Description HIV-infected individuals bear a disproportionate disease burden of HPV-related diseases suggesting more rapid progression from HPV acquisition to malignancy. HIV infected women have a 2-22 fold increased risk for cervical cancer compared to uninfected women. The quadrivalent HPV vaccine marketed as "Gardasil" has demonstrated efficacy against type specific HPV infections known to cause 70% cervical cancer (HPV 16 & 18) and HPV 6 & 11 known to cause 90% of anogenital warts in populations of HIV negative young women. Since the risk of HPV exposure persists throughout a person's sexual life, the duration of protection, especially when the vaccine is given in the pre-adolescent period, is critical to overall vaccine effectiveness. Extended follow up of HIV-uninfected individuals has shown sustained response to HPV vaccine for 8.4 and 6 years respectively to the bivalent and quadrivalent vaccines. However, other vaccines such as the hepatitis B vaccine have been shown to require additional dosages to be effective among HIV-infected persons. Data on immunogenicity of the HPV vaccine among HIV infected adolescents is limited to a 12 month follow up period. Current HPV vaccine guidelines target pre-sexual adolescents. Since the risk of HPV exposure persists throughout an individual's sexual life, the duration of protection provided by vaccination is critical to the overall vaccine effectiveness. Duration of sustained HPV 6/11/16/18 antibody response is directly related to vaccine effectiveness and determines the need for booster dosing. The investigators therefore propose to extend follow up of 179 girls and boys in Kenya, age 9-14 years who have received 3 doses of the quadrivalent 'Gardasil' vaccine and assess for immunogenicity annually. Study Location: Partners in Prevention, Thika site
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Kenyatta National Hospital.